前列安丸治疗慢性非细菌性前列腺炎

目的:观察前列安丸对慢性非细菌性前列腺炎(CNP)的临床疗效。方法:将176例肝郁血瘀型CNP患者,采用数字表方法随机分为治疗组和对照组各88例,治疗组口服前列安丸,每次10 g,每天3次;对照组口服前列康片,每次5片,每日3次。两组治疗4周后观察两组治疗前后临床疗效,慢性前列腺炎症状评分(NIH-CPSI),中医症状积分,前列腺液参数和尿流率的变化。结果:两组经过4周治疗后,治疗组总有效率(90.97%)明显高于对照组总有效率(68.60%)(P0.01);治疗组NIH-CPSI总评分(9.75±3.67)分,中医症状积分(6.15±3.24)分,较对照组(15.83±3.71),(9.36±5.12)分,显著降低(P0.01);治疗组前列腺液白细胞和卵磷脂小体积分(0.86±0.74),(0.75±0.63)分,较对照组(1.54±0.37),(1.40±0.25)分,显著改善(P0.01),治疗组最大尿流率(MFR)和平均尿流率(AFR)(22.35±4.26),(12.35±2.24)m L·s-1,较对照组(16.54±2.73),(10.12±2.65)m L·s-1,显著提高(P0.01)。结论:前列安丸能够显著降低CNP患者的NIH-CPSI评分、中医症状积分、改善前列腺液参数和尿流率,临床疗效显著。

Effect of Qianliean Pills in Treatment of Chronic Non Bacterial Prostatitis

Objective: The aim of this study was to observe the clinical efficacy of prostant on chronic non-bacterial prostatitis(CNP). Method: In this study, one hundred and seventy-six cases of liver depression and blood stasis patients with this disease were randomly divided into the treatment group and the control group using digital table method, with 88 cases in each group. The treatment group was given oral Qianliean pills 10 grams every time,3 times a day, while the control group was given oral Qianlie Kang tablets, 5 tablets every time, 3 times a day. The clinical curative effect, chronic iflammatory prostate(NIH-CPSI) score, traditional Chinese medicine(TCM) symptom score, prostate fluid parameters and urine flow rate before and after treatment were observed four weeks after treatment in the two groups. Result: After the treatment for four weeks, the total effective rate in treatment group (90.97%) was significantly higher than that in control group (68.60%) (P <0.01).The NIH-CPSI total score(9.75±3.67),TCM symptom score(6.15±3.24)in treatment group significantly reduced compared with the control group (15.83±3.71),(9.36±5.12)(P <0.01). In the treatment group, the prostatic fluid white blood cells and lecithin body score(0.86±0.74),(0.75±0.63)improved significantly compared with the control group (1.54±0.37),(1.40±0.25)(P <0.01). In treatment group, maximal urinary flow rate (MFR) and average urinary flow rate (AFR) (22.35±4.26),(12.35±2.24) mL·s^-1] increased significantly compared with the control group(16.54±2.73),(10.12±2.65)mL·s^-1] (P <0.01). Conclusion: Qianliean pellet can significantly decrease the NIH-CPSI score and TCM symptom score in patients with CNP, and improve the prostatic fluid parameters and urine flow rate. The clinical curative effect is remarkable.